Thomas Hope

Thomas Hope has been at the forefront of developing fibroblast activation protein (FAP)-targeted radioligand approaches as a pan-cancer theranostic strategy, leveraging the near-universal expression of FAP on cancer-associated fibroblasts across solid tumor types. His clinical studies with FAPI PET tracers have demonstrated superior tumor-to-background ratios compared to FDG-PET in many cancer types including pancreatic, breast, and colorectal cancers. He is advancing FAP-targeted radioligand therapy using both Lu-177 and Ac-225 labeled FAPI compounds, with early clinical results showing tumor responses in multiple cancer types. His work extends the radioligand therapy paradigm beyond PSMA-positive prostate cancer to potentially all solid tumors with desmoplastic stroma.